drugset / Trial / NCT00879138

Efficacy and Safety of VA106483 in Elderly Males

NCT00879138 ↗

Phase 1/2 Completed 27 enrolled Vantia Ltd Veeda Clinical Research · collab
RandomizedCrossoverDouble-blind

Summary

A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both single and multiple oral doses of VA106483 at three dose levels, under conditions of controlled hydration.

Timeline

Start
2008-08
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject VA106483 Small molecule 2 mg Oral
Subject VA106483 Small molecule 4 mg Oral
Subject VA106483 Small molecule 8 mg Oral

Indications

No indication recorded.